84 results about "Previously treated" patented technology

A method of treating, preventing or ameliorating one or more symptoms associated with hepatitis C virus (HCV) in a patient in whom either the HCV is of Genotype 1 and/or the patient was previously treated with interferon and the previous interferon therapy was ineffective to treat the one or more symptoms associated with HCV, comprising administering to such a patient an effective amount of at least one compound of formulae I-XXVI of which the following structural formula is exemplary

or a pharmaceutically acceptable salt, solvate or ester thereof. Optional combined administration of said at least one compound with an interferon or pegylated interferon and/or ribaviron is also contemplated.

A method of growing photosynthetic organisms comprising providing the organisms with flue gases from a fossil-fuel power plant, the gases being previously treated by desulfurization. The carbon dioxide (CO₂) concentration of the flue gases may be increased over the CO₂ concentration as released from the power plant. Also disclosed is a method for producing ω fatty acids and bio-fuels comprising growing microalgae by providing said microalgae with flue gases from a fossil-fuel power plant.

Provided herein are combinations that include an HDACi and a PD-1 inhibitor that are useful for treating cancer, including reducing and/or preventing cancer metastasis. The combination is also useful for treating cancer that has been previously treated with a PD-L1 inhibitor.

The present invention relates to methods for the treatment and repair of cartilage, including cartilage damaged by injury or cartilagenous disorders, including degenerative cartilagenous disorders such as arthritis, comprising the administration of IL-17 and/or LIF antagonists (e.g., anti-IL-17 and anti-LIF antibodies). Optionally, the administration may be in combination with a cartilage agent (e.g., peptide growth factor, catabolism antagonist, osteo-, synovial, anti-inflammatory factor). Alternatively, the method provides for the treatment and repair of cartilage damaged by injury or cartilagenous disorders comprising the administration of IL-17 or LIF antagonists in combination with standard surgical techniques. Alternatively, the method provides for the treatment and repair of cartilage damaged by injury or cartilagenous disorders comprising the administration of chondrocytes previously treated with an effective amount of IL-17 and/or LIF antagonist. Alternatively, the method provides for the treatment of a mammal suffering from a cartilagenous disorder, comprising the adminstration of a therapeutically effective amount of an IL-17 and/or LIF antagonist.

Scheduling techniques are disclosed that employ one or more predictive scheduling classification algorithms configured to exploit historical data of previously scheduled and completed medical procedures. Thus, a new patient that is similarly-situated to previously treated patients can have a medical procedure automatically predicted and scheduled based on historical procedure data associated with those previously treated patients.

Compositions, methods and kits for providing hemostasis and sealing of exposed tooth pulp and/or pink dentin. The inventive methods and kits employ propylhexedrine as a hemostatic agent, such as in the form of an aqueous composition of propylhexedrine hydrochloride, and an adhesive sealant composition. The propylhexedrine solution is advantageously applied to the exposed pulp and pink dentin by means of a cotton pellet or other absorbent applicator. The adhesive sealant composition is advantageously applied to exposed pulp and pink dentin, which has been previously treated with the propylhexedrine solution, by means of a syringe. The adhesive sealant composition may include an alkyl methacrylate having an oxyphosphorus group, a polymerization initiator and an antimicrobial agent, such as calcium hydroxide. The adhesive sealant composition can be polymerized in situ and is used to prevent ingress by microorgaism into an area of the tooth being treated.

A system and method for converting measured wavefront data into an ablation profile for correcting visual defects includes providing measured wavefront data on an aberrated eye by a method such as known in the art. The measured wavefront data are correlated with accumulated data on previously treated eyes. Next an adjustment is applied to the measured wavefront data based upon the correlating step. This adjustment is used to form adjusted wavefront data for input to a wavefront data correction algorithm to calculate an ablation profile therefrom. The wavefront data correction algorithm may be modeled as, for example, Zernike polynomials with adjusted coefficients.

PCT No. PCT/JP97/01748 Sec. 371 Date Jul. 7, 1998 Sec. 102(e) Date Jul. 7, 1998 PCT Filed May 26, 1997 PCT Pub. No. WO98/20081 PCT Pub. Date May 14, 1998A carrier particle (A) is previously treated with a compound (B) such as a silane coupling agent, if necessary. To the carrier particle, a free functional group is introduced by allowing a reactive group of the carrier particle (A) to react with a compound (C) such as a bisoxazoline compound. As a result, a reactive particle represented by the following formula (I): [C-(B1)m]n-A-[(B2)p-D]q (I) wherein A is a carrier particle, C is an organic group having at least one free functional group, D is a hydrophilic or hydrophobic group, B1 is an organic group connecting the carrier particle A to the organic group C and B2 is an organic group connecting the carrier particle A to the hydrophilic or hydrophobic group; n is an integer of not less than 1, m and p are 0 or 1, q is 0 or an integer of not less than 1, m and p may be different according to n and q; and having a number of active sites can be obtained. A hydrophilic or hydrophobic group may be introduced to the carrier (A).

A method of growing chondrocytes on an allograft cancellous bone structure which had been previously treated by demineralization to form a cartilage repair implant comprises isolating allograft chondrocytes from articular cartilage of a donor other than the patient on which the implant is to be used, cultivating the isolated chondrocytes in a medium to obtain a dedifferentiated fibroblast-like phenotype, placing an at least partially demineralized allograft cancellous bone structure carrier having at least one surface prepared for cell seeding in a culture vessel; adding the cultivated dedifferentiated chondrocytes to a demineralized surface of the cancellous bone structure carrier, and incubating the cancerous bone structure carrier for a period of time of at least 40 days to obtain an implant with a cartilage layer which ranges from about 2 mm to 5 mm n thickness.

This invention concerns extrudates having high surface area materials and at least one metal ion adsorbed onto the high surface area material. The extrudates may be breathable films, multilayer laminates and pultruded articles. The extrudates may be made into storage and packaging material to reduce odor and retard the ripening of fruit. The extrudates, if in the form of a breathable film or multilayer laminate may be used as outer cover material for personal care products like diapers, adult incontinence products, training pants and the like. The high surface area particle-containing extrudate may be made by adding modified nanoparticles to a filler before the filler is treated with a fatty acid. Alternatively, a filler previously treated with a fatty acid may be modified by subjecting the filler to sonic energy in the presence of an aqueous solution of metal ions and nanoparticles.

The present invention is directed to compounds, compositions thereof, and the use of the compounds and compositions for the treatment and prevention of breast cancer. In one embodiment, the present invention relates to the use of a substituted triphenyl butene or prodrug thereof for the treatment of breast cancer in mono-therapy or in combination therapy, or for a reduction in the recurrence rate of previously-treated breast cancer.

A buoyancy flushing apparatus is disclosed which comprises a reservoir for accumulating liquid, having an inlet for receiving liquid and an outlet chamber recessed in a bottom wall of the reservoir. The outlet chamber includes an outlet for draining liquid out of the reservoir. The apparatus further comprises an outlet valve movable between a down position where liquid accumulates in the reservoir and a raised position where liquid accumulated in the reservoir is flushed out via the outlet. The outlet valve comprises a ballast unit sized and shaped to fit loosely in the outlet chamber when said valve is in the down position; and a float unit topping the ballast unit to move the valve in the raised position by buoyancy when a sufficient amount of liquid is accumulated in the reservoir, thereby providing a passageway for liquid between the bottom wall of the reservoir and the valve leading to the outlet in the outlet chamber to flush liquid out of the reservoir. Guiding means are provided for guiding the outlet valve between the down position and the raised position. The apparatus can be used for applications such as water treatment and irrigation. It could advantageously be used for directing and spreading waste water previously treated in a septic tank to different sanitary treating fields.

Disclosed is an antibacterial treatment method which has no limitation in the scope of a material to be treated and which enables to reduce the time or cost required for the antibacterial testament. Specifically disclosed is an antibacterial treatment method using an antibacterial agent comprising a powder produced by mixing a microorganism selected from Bacillus sphaericus, Bacillus subtilis and Bacillus thuringiensis with a cattle feces which is previously treated at a high temperature of 60 to 150° C., wherein the material to be treated and the antibacterial agent are arranged under a non-contacting condition to inhibit the growth of a target bacterium in the material.

The present invention is related to an integrated process for the treatment and valorization of organic waste, the process comprising the steps of treating the organic waste with a microorganism treatment for producing gas; separating the organic waste resulting from step a) into a liquid fraction and a solid fraction; and using the liquid fraction resulting from step b) as a fertilizer. The present invention also relates to the use of a liquid fraction obtained from the solid liquid separation of an organic waste previously treated by a microorganism treatment as a fertilizer.

Methods for screening specific biological endpoints that can be utilized to identify potential therapeutic agents for METH addiction. In one aspect of the invention, the methods involve reversal of behavioral sensitization and/or conditioned place preference in an animal previously treated with METH in the presence of a known amount of a 5-HT_2A/2C antagonist or a selective 5-HT_2C antagonist, and reversal of the electrophysiological endpoints in a METH-treated animal in the presence of a known amount of the 5-HT_2A/2C antagonist or the selective 5-HT_2C antagonist. Therapeutic treatment methods for reversing the set of biological endpoints that change in the METH drug addict using mirtazapine, SDZ SER 082, and related serotonin antagonists are also provided. The methods of the invention may be utilized in the identification of potential new therapies for multiple drugs of abuse.

A method for reducing or maintaining platelet inhibition in a patient by administering cangrelor prior to an invasive procedure is described. The method of this invention can be used for patients in need of antiplatelet therapy or at risk of thrombosis. The method can further be used in patients who were previously treated with long-acting platelet inhibitors without increasing the risk of excessive bleeding.